BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18199869)

  • 1. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB; Holman R; Drucker DJ
    N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
    [No Abstract]   [Full Text] [Related]  

  • 2. Which oral agent to use when metformin is no longer effective?
    Bannon M
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract]   [Full Text] [Related]  

  • 3. What to add in with metformin in type 2 diabetes?
    Petrie JR; Adler A; Vella S
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 5. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB; Molitch ME
    N Engl J Med; 2013 Oct; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract]   [Full Text] [Related]  

  • 7. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
    Dailey G
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting type 2 diabetes.
    Schwanstecher C; Schwanstecher M
    Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 13. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
    Sisson EM; Mills J; Chin L
    Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
    [No Abstract]   [Full Text] [Related]  

  • 15. [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
    André P
    Rev Epidemiol Sante Publique; 1999 Mar; 47(1):93-5. PubMed ID: 10214683
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
    Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
    Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond insulin: what else might help?
    Scheiner G
    Diabetes Self Manag; 2014; 31(1):30, 32-4. PubMed ID: 24640060
    [No Abstract]   [Full Text] [Related]  

  • 20. Add-on therapies to metformin for type 2 diabetes.
    Shomali M
    Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.